DGAP-News: VUCCC P/L Announces Lodgement in Germany of Patent for Treatment of Type I Diabetes
(firmenpresse) - VUCC PTY LTD / Miscellaneous
03.03.2010 12:40
Dissemination of a Financial News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
VUCCC P/L Announces Lodgement in Germany of Patent for Treatment of Type I
Diabetes
Zurich, Switzerland and Melbourne, Australia
is pleased to announce that it has filed for patent protection of its
ground breaking new treatment regimen for Type 1 'insulin-dependent'
diabetes, through the European Patent Office.
Developed with science emanating from collaborators at 4 European
universities (Tübingen University, Heidelberg University, Manchester&Uppsala Universities), it is the result of over a decade of clinical trial
work in with over 15,000 patients, carried out in conjunction with the
German Ministry of Health and other partners.
VUCCC states that the treatment has cured the disease in more than 80% of
sufferers treated and does not suffer a relapse during the first 24 months
after successfully completing the treatment has remained disease free.
The treatment regimen is closely controlled in conjunction with the
patient's doctor, guided by diagnostic testing proprietary to VUCCC. This
development will see VUCCC establish diagnostic reference centres across
Europe, to ascertain patients' potential treatment outcomes. VUCCC also
states that it will establish a centralised teaching centre, for
controlling the standard of the ongoing testing program.
The company estimates there will be an average long term saving to the
German Ministry of Health of EUR 70 billion per year. The estimate is based
on existing costs of patient management and the number of patients
treatable with this technology.
VUCCC will have an agreement in place with a major pharmaceutical company
and an international laboratory network for marketing, distribution, sales
and related laboratory services for the treatment. It will be launched in
Germany in 2010. Release in other countries will follow.
This development represents the next step in two years of commercialisation
work between VUCCC P/L and P+S Business Advisory, a division of P + S
Business Brokers, of Melbourne, Australia, in bringing this technology to
market. Further patents are pending.
VUCCC P/L plans further investment and would welcome enquiries from serious
parties. Contact can be made with P+S Business Advisory, 570 Glenhuntly
Road, Elsternwick, VIC, 3185, Australia diabetes(at)psbb.com.au.
Media Enquiries: For further details please contact Dr. Eva Reuter in
Germany, +49 (0) 177 60 58 804, e.reuter(at)dr-reuter.eu.
About VUCCC P/L
VUCCC P/L is an emerging leader in autoimmune&metabolic diseases. The
company is involved in commercialising treatments and diagnostic tests in
these areas, presenting solutions to real&costly disease problems facing
healthcare providers globally.
03.03.2010 12:40 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Language: English
Company: VUCC PTY LTD
570 Glenhuntly Road
VIC3185 Elsterwick
Australien
Internet: www.psbb.com.au
End of News DGAP News-Service
---------------------------------------------------------------------------
Datum: 03.03.2010 - 12:40 Uhr
Sprache: Deutsch
News-ID 17141
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: VUCCC P/L Announces Lodgement in Germany of Patent for Treatment of Type I Diabetes"
steht unter der journalistisch-redaktionellen Verantwortung von
VUCC PTY LTD (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
